A Case Series Examining the 1-year Follow-up Outcomes of Myocarditis Associated with COVID-19 Vaccination

A Case Series Examining the 1-year Follow-up Outcomes of Myocarditis Associated with COVID-19 Vaccination

Background: COVID-19 messenger RNA (mRNA) vaccine-related myocarditis, though rare, primarily affects young males and often presents its symptoms within the 1st week postvaccination. Aims and Objectives: To assess the long-term outcomes of individuals diagnosed with myocarditis following COVID-19 va...

Full description

Saved in:
Bibliographic Details
Main Authors: Mohammed Thamer Ali, Ammar Chapra, Samah F. A. Mohamed, Abdel Naser Ghareeb, Maryam Al Kuwari, Sabir Abdul Karim, Tahir Hamid, Emad Ahmed Ali Hassan, Awad Al Qahtani, Nidal Asaad, Jassim Al Suwaidi
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2024-10-01
Series:Heart Views
Subjects:
covid-19 vaccine
myocarditis
severe acute respiratory syndrome coronavirus 2
Online Access:https://journals.lww.com/10.4103/heartviews.heartviews_62_24
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: COVID-19 messenger RNA (mRNA) vaccine-related myocarditis, though rare, primarily affects young males and often presents its symptoms within the 1st week postvaccination. Aims and Objectives: To assess the long-term outcomes of individuals diagnosed with myocarditis following COVID-19 vaccination. Materials and Methods: We conducted a case series analysis involving 17 patients diagnosed with inflammatory myocarditis. Results: Symptoms in these patients typically appeared 24–96 h after receiving the COVID-19 mRNA vaccine. Fortunately, the prognosis for these patients is generally favorable, characterized by good short-term recovery and minimal long-term consequences. Follow-up cardiac magnetic resonance imaging (CMR) among our patients revealed alongside a preserved ejection fraction, the absence of fibrosis in 7 out of 13 (54%) patients with minimal residual fibrosis in 5 (38%) patients, whereas the remaining one patient demonstrated fibrosis consistent with hypertrophic cardiomyopathy. Conclusion: Despite the seemingly benign nature of COVID-19 mRNA vaccine-related myocarditis thus far, it is crucial to emphasize the necessity of prolonged clinical and CMR follow-up exceeding 1 year. Extended monitoring is essential to gain a deeper understanding of the true nature of this condition and its potential implications. This comprehensive approach will contribute significantly to ensuring the ongoing safety and efficacy of COVID-19 vaccination programs.
ISSN:1995-705X
0976-5123

Similar Items